Abstract：
OBJECTIVE: To briefly review the latest updates in management in giant cell arteritis, an autoimmune vasculitis affecting the medium to large vessels.
RESULTS: Here, we review the known and newer trends in management of giant cell arteritis. While high dose glucocorticoids remain the mainstay of therapy, immunosuppressive medications are increasingly utilized to reduce the burden and risk of long-term glucocorticoid use. Published guidelines by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) suggest early use of steroid-sparing immunosuppressive medications in patients with recently diagnosed or relapsing giant cell arteritis. Immunosuppressive medications include oral small molecules such as methotrexate and leflunomide and biologics, including the recently Federal Drug Administration (FDA) approved tocilizumab. Glucocorticoids remain the cornerstone of management for newly diagnosed disease but with the increasing use of medications such as IL-6 inhibitors, patients are decreasing steroid use within weeks, thereby limiting risks associated with long-term steroid use.
RESULTS: Here, we review the known and newer trends in management of giant cell arteritis. While high dose glucocorticoids remain the mainstay of therapy, immunosuppressive medications are increasingly utilized to reduce the burden and risk of long-term glucocorticoid use. Published guidelines by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) suggest early use of steroid-sparing immunosuppressive medications in patients with recently diagnosed or relapsing giant cell arteritis. Immunosuppressive medications include oral small molecules such as methotrexate and leflunomide and biologics, including the recently Federal Drug Administration (FDA) approved tocilizumab. Glucocorticoids remain the cornerstone of management for newly diagnosed disease but with the increasing use of medications such as IL-6 inhibitors, patients are decreasing steroid use within weeks, thereby limiting risks associated with long-term steroid use.
摘要：
目的：简要回顾巨细胞动脉炎管理的最新更新，影响中大血管的自身免疫性血管炎。
结果：这里，我们回顾了巨细胞动脉炎治疗的已知和最新趋势。虽然高剂量糖皮质激素仍然是治疗的主要手段，免疫抑制药物越来越多地用于降低长期使用糖皮质激素的负担和风险.美国风湿病学会（ACR）和欧洲抗风湿病联盟（EULAR）发布的指南建议在最近诊断或复发的巨细胞动脉炎患者中早期使用保留类固醇的免疫抑制药物。免疫抑制药物包括口服小分子药物，如甲氨蝶呤和来氟米特，包括最近联邦药物管理局（FDA）批准的托珠单抗。糖皮质激素仍然是治疗新诊断疾病的基石，但随着IL-6抑制剂等药物的使用越来越多，患者在几周内减少了类固醇的使用，从而限制与长期使用类固醇相关的风险。
结果：这里，我们回顾了巨细胞动脉炎治疗的已知和最新趋势。虽然高剂量糖皮质激素仍然是治疗的主要手段，免疫抑制药物越来越多地用于降低长期使用糖皮质激素的负担和风险.美国风湿病学会（ACR）和欧洲抗风湿病联盟（EULAR）发布的指南建议在最近诊断或复发的巨细胞动脉炎患者中早期使用保留类固醇的免疫抑制药物。免疫抑制药物包括口服小分子药物，如甲氨蝶呤和来氟米特，包括最近联邦药物管理局（FDA）批准的托珠单抗。糖皮质激素仍然是治疗新诊断疾病的基石，但随着IL-6抑制剂等药物的使用越来越多，患者在几周内减少了类固醇的使用，从而限制与长期使用类固醇相关的风险。
